Background illustration for clinical trials search

Paid Clinical Trials Plainfield

Discover 2,367 paid clinical trials in Plainfield, Illinois. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

Ischemic Preconditioning in Osteoarthritis and Back Pain

for
Low Back Pain, Knee Osteoarthritis
Location: Chicago IL
Sponsor: University of Illinois at Chicago

Sex: All

Age: 50+

Code: NCT07003113

Recruiting
Active & Responsive

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

for
Acute Myeloid Leukemia
Location: Chicago IL, Indianapolis IN, Iowa City IA, St Louis MO,
Sponsor: PedAL BCU, LLC

Sex: All

Age: 0 - 21

Code: NCT05183035

Phase3, Recruiting
Active & Responsive

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: Arlington Heights IL, Chicago IL, Peoria IL, Madison WI,
Sponsor: Immuneering Corporation

Sex: All

Age: 18+

Code: NCT07562152

Phase3, Recruiting
Active & Responsive

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

for
Generalized Myasthenia Gravis
Location: Chicago IL, Greenfield WI, East Lansing MI,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06744920

Phase3, Recruiting
Active & Responsive

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

for
Ductal Carcinoma in Situ
Location: Chicago IL, Saint Paul MN, Minneapolis MN,
Sponsor: QuantumLeap Healthcare Collaborative

Sex: Female

Age: 18+

Code: NCT06075953

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Chicago IL, Madison WI, Indianapolis IN, St Louis MO,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase1, Recruiting
Active & Responsive

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

for
Schizophrenia Spectrum and Other Psychotic Disorders,
Location: Chicago IL, Athens GA, Dallas TX, Hartford CT,
Sponsor: Beth Israel Deaconess Medical Center

Sex: All

Age: 18 - 40

Code: NCT06740383

Recruiting
Active & Responsive

A Study of PHST001 in Advanced Solid Tumors

for
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer,
Location: Chicago IL, Grand Rapids MI, Ann Arbor MI, Denver CO,
Sponsor: Pheast Therapeutics

Sex: All

Age: 18+

Code: NCT06840886

Phase1, Recruiting
Active & Responsive

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for
Carcinoma, Non-Small-Cell Lung
Location: Chicago IL, Indianapolis IN, Cincinnati OH,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06623422

Phase3, Recruiting
Active & Responsive

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

for
Emphysema, Pulmonary, Emphysema or COPD
Location: Chicago IL, Peoria IL, Milwaukee WI, Detroit MI,
Sponsor: Pulmonx Corporation

Sex: All

Age: 40 - 70+

Code: NCT06035120

Recruiting
Active & Responsive

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

for
Lymphoma, Non-Hodgkin, B-cell Lymphoma,
Location: Chicago IL, Milwaukee WI, Iowa City IA, Rochester MN,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07101328

Phase1, Recruiting
Active & Responsive

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for
Urothelial Carcinoma
Location: Chicago IL, Indianapolis IN, St Louis MO, Cleveland OH,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05562830

Phase1, Phase2, Recruiting
Active & Responsive

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

for
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Location: Chicago IL, New York NY, Boston MA, Houston TX,
Sponsor: Elevar Therapeutics

Sex: All

Age: 18+

Code: NCT07359820

Phase2, Recruiting
Active & Responsive

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

for
Bladder Cancer
Location: Chicago IL, Cleveland OH, Salt Lake City UT,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07232602

Phase1, Phase2, Recruiting
Active & Responsive

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

for
Short Bowel Syndrome
Location: Chicago IL, St Louis MO, Nashville TN, Omaha NE
Sponsor: Zealand Pharma

Sex: All

Age: 18 - 70+

Code: NCT07197944

Phase3, Recruiting
Active & Responsive

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

for
Type I Diabetes
Location: Chicago IL, Birmingham AL, Aurora CO, Renton WA,
Sponsor: Op-T LLC

Sex: All

Age: 18 - 50

Code: NCT06964087

Phase2, Recruiting
Active & Responsive

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Chicago IL, St Louis MO, Detroit MI, Nashville TN,
Sponsor: ModernaTX, Inc.

Sex: All

Age: 12+

Code: NCT05533697

Phase1, Phase2, Recruiting
Active & Responsive

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

for
Ulcerative Colitis
Location: Chicago IL, St Louis MO, Ypsilanti MI, Cincinnati OH,
Sponsor: Takeda

Sex: All

Age: 18 - 65

Code: NCT06095128

Recruiting
Active & Responsive

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

for
Non-small Cell Lung Cancer, NSCLC
Location: Chicago IL, Ypsilanti MI, Minneapolis MN, Kitchener,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06422143

Phase3, Recruiting
Active & Responsive

Food and Metabolism Study

for
Prediabetes, Insulin Resistance, Triglycerides,
Location: Chicago IL
Sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology

Sex: All

Age: 40 - 70

Code: NCT07624500

Recruiting